IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Human bone marrow–derived mesenchymal stromal cells (MSCs) inhibit proliferation of activated T cells, and IFN-γ plays an important role in this process. This IFN-γ–licensed veto property is IDO-dependent. To further decipher the mechanistic underpinnings of MSC veto function on T cells, we investigated the effect of MSCs and IFN-γ–licensed MSCs on T cell effector function as assayed by cytokine secretion of T cells. Although MSCs and IFN-γ–licensed MSCs inhibit T cell proliferation, only IFN-γ–licensed MSCs significantly inhibit Th1 cytokine (IFN-γ, TNF-α, and IL-2) production by T cells. Additionally, IFN-γ–licensed MSCs inhibit T cell degranulation as well as single, double, and triple cytokine–producing T cells. Although IFN-γ–licensed MSCs upregulate their IDO activity, we found that MSC IDO catalytic function is dispensable with regard to MSC-driven inhibition of T cell effector function. Novel flow cytometry based functional screening of MSC-expressed, IFN-γ–licensed inhibitory molecules identified B7H1 and B7DC/PD1 pathways as essential effectors in blocking T cell function. Small interfering RNA–mediated blocking of B7H1 and B7DC reverses the inhibitory potential of IFN-γ–licensed MSCs on T cell effector function. Mechanistic analysis revealed that clustering of MHC and coinhibitory molecules are indispensable for the inhibitory effect of IFN-γ MSCs. Although exogenous IL-2 reverses B7H1-Ig–mediated inhibition of T cell proliferation, it does not affect the veto function of IFN-γ MSCs on both T cell proliferation and effector function. Our results reveal a new immunosuppressive property of IFN-γ–licensed MSCs that inhibits T cell effector function independent of IDO but through the ligands for PD1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Chinnadurai et al. elegantly showed that MSCs can inhibit PBMC proliferation through PD1/PD-L1 [48].”
In the citing paper
“IFN-γ-primed MSCs have demonstrated to block T cell proliferation in a dose-dependent manner and to abrogate the production of IFN-γ, IL-2 and TNF-α, three cytokines with a role in T cell-derived immune response [136].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [136]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“M arrowmesenchymal stromal cells (MSCs) play a role in maintaining the hematopoietic niche, regulate marrow immune homeostasis, and can differentiate into bone, cartilage, and adipocytes as a mesenchymal progenitor pool (1, 2).”
BackgroundMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 1×
“The therapeutic potential of transfused MSCs has been demonstrated in animal models of experimental autoimmune encephalitis, diabetes, rheumatoid arthritis, myocardial infarction, acute lung injury, retinal degeneration, acute renal failure, and transplant rejection (9, 10).”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 1×
“Therefore, an analysis of MSC immune plasticity in response to exogenous IFN-g stimulation (6, 22) and how this serves as an immune checkpoint to T cell activity are of physiological and translational interest.”
MethodCentral Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067 · cited 1×
“Once naive T cells are exposed to an activation signal they proliferate, and a subset becomes effector T cells as manifested by cytokine secretion and degranulation, based on their memory status (23, 24).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734 · cited 1×
“In human phase II clinical trials, MSCs were shown to be effective in treating graft-versus-host disease (11), although study of an industrial MSC product in a phase III trial was negative (12–14).”
BackgroundFriedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724 · cited 1×
“Although endogenous clonogenic marrow MSCs represent a small minority of all nucleated cells in marrow space, typically 1:100,000, these same cells possess a robust mitogenic potential when cultured ex vivo (3, 4).”
BackgroundThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Research works printed but not linked: 1
- Jeremias, 1998, TRAIL/Apo-2-ligand-induced apoptosis in human T cells, Eur. J. Immunol., 28, 143, 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3 · DOI · Paper page
Cited by
Challenges and advances in clinical applications of mesenchymal stromal cells
Zhou, T., Yuan, Z., Weng, J., Pei, D., Du, X., He, C., & Lai, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01037-x · Cited by 712
Immune modulation by mesenchymal stem cells
Jiang, W., & Xu, J. (2020) · Cell Proliferation · doi:10.1111/cpr.12712 · Cited by 650
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623
“functions through the upregulation of programmed cell death-1 ligands (PDL-1), at the same time, but independently of IDO upregulation [20].”
BackgroundGalipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R. J., DeBruijn, J., Dominici, M., Fibbe, W. E., Gee, A. P., Gimble, J. M., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.11.008 · Cited by 520
Self-citation
Metadata
- Authors
- Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J.
- Affiliations
- Emory University (US)
- Corresponding author
- Chinnadurai, Raghavan
- Galipeau, Jacques
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02
- Volume
- 192
- Issue
- 4
- Pages
- 1491-1501
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147854121
- Cited by
- 266
- References
- 63
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 30 · 2022: 15 · 2021: 28 · 2020: 31 · 2019: 19 · 2018: 22 · 2017: 25 · 2016: 24 · 2015: 21 · 2014: 10
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (T32AI007610)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mesenchymal stem cells, T cell effector function, PD-L1, PD-1, T cell degranulation, interleukin-2, T cell proliferation inhibition, bone marrow-derived stromal cells
- MeSH terms
- Bone Marrow Cells, Cells, Cultured, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Tumor Necrosis Factor-alpha, Cell Degranulation, Th1 Cells, RNA Interference, RNA, Small Interfering, Cell Proliferation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mesenchymal Stem Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.